耐喹诺酮淋病奈瑟菌：DNA 回旋酶 GyrA 亚基和拓扑异构酶 IV 的 ParC 亚基改变与抗菌药物敏感性谱的相关性
Quinolone-resistant Neisseria gonorrhoeae: correlation of alterations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV with antimicrobial susceptibility profiles.
作者信息
Deguchi T, Yasuda M, Nakano M, Ozeki S, Ezaki T, Saito I, Kawada Y
机构信息
Department of Urology, Gifu University School of Medicine, Japan.
出版信息
Antimicrob Agents Chemother. 1996 Apr;40(4):1020-3. doi: 10.1128/AAC.40.4.1020.
Abstract
Fifty-five clinical strains of Neisseria gonorrhoeae were examined for mutations in the gyrA and parC genes and for antimicrobial susceptibility profiles. The MICs of quinolones for 31 strains with alterations in GyrA were significantly higher than the MICs for 24 strains without such alterations. Eleven strains with alterations in both GyrA and ParC were significantly more resistant to fluoroquinolones than those with alterations in GyrA alone. The MICs of cephalosporins for these strains were also significantly higher than those for other strains.
摘要
对55株淋病奈瑟菌临床菌株进行了gyrA和parC基因突变及抗菌药物敏感性分析。31株GyrA发生改变的菌株对喹诺酮类药物的最低抑菌浓度（MIC）显著高于24株未发生此类改变的菌株。11株GyrA和ParC均发生改变的菌株对氟喹诺酮类药物的耐药性显著高于仅GyrA发生改变的菌株。这些菌株对头孢菌素类药物的MIC也显著高于其他菌株。
相似文献
1
Quinolone-resistant Neisseria gonorrhoeae: correlation of alterations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV with antimicrobial susceptibility profiles.
Antimicrob Agents Chemother. 1996 Apr;40(4):1020-3. doi: 10.1128/AAC.40.4.1020.
2
Correlation of in vitro susceptibilities to newer quinolones of naturally occurring quinolone-resistant Neisseria gonorrhoeae strains with changes in GyrA and ParC.
Antimicrob Agents Chemother. 2001 Mar;45(3):734-8. doi: 10.1128/AAC.45.3.734-738.2001.
3
In vitro selection of fluoroquinolone-resistant Neisseria gonorrhoeae harboring alterations in DNA gyrase and topoisomerase IV.
J Urol. 2000 Sep;164(3 Pt 1):847-51. doi: 10.1097/00005392-200009010-00060.
4
Antimicrobial activity of a new fluoroquinolone, DU-6859a, against quinolone-resistant clinical isolates of Neisseria gonorrhoeae with genetic alterations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV.
J Antimicrob Chemother. 1997 Feb;39(2):247-9. doi: 10.1093/jac/39.2.247.
5
Susceptibilities of Neisseria gonorrhoeae isolates containing amino acid substitutions in GyrA, with or without substitutions in ParC, to newer fluoroquinolones and other antibiotics.
Antimicrob Agents Chemother. 2000 Jan;44(1):192-5. doi: 10.1128/AAC.44.1.192-195.2000.
6
Serotyping of quinolone-resistant Neisseria gonorrhoeae isolates with alterations in GyrA and ParC.
J Antimicrob Chemother. 1998 Mar;41(3):418-20. doi: 10.1093/jac/41.3.418.
7
Detection of mutations in the gyrA and parC genes in quinolone-resistant clinical isolates of Enterobacter cloacae.
J Antimicrob Chemother. 1997 Oct;40(4):543-9. doi: 10.1093/jac/40.4.543.
8
Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC.
Chemotherapy. 1997 Jul-Aug;43(4):239-44. doi: 10.1159/000239573.
9
Development of fluoroquinolone resistance and mutations involving GyrA and ParC proteins among Neisseria gonorrhoeae isolates in Japan.
J Urol. 1998 Jun;159(6):2215-9. doi: 10.1016/S0022-5347(01)63308-1.
10
Characterization of Neisseria gonorrhoeae strains with decreased susceptibility to fluoroquinolones isolated in Greece from 1996 to 1999.
J Clin Microbiol. 2000 Sep;38(9):3489-91. doi: 10.1128/JCM.38.9.3489-3491.2000.
引用本文的文献
1
Target-Mediated Fluoroquinolone Resistance in : Actions of Ciprofloxacin against Gyrase and Topoisomerase IV.
ACS Infect Dis. 2024 Apr 12;10(4):1351-1360. doi: 10.1021/acsinfecdis.4c00041. Epub 2024 Mar 4.
2
gyrA Mutations in Mycoplasma genitalium and Their Contribution to Moxifloxacin Failure: Time for the Next Generation of Resistance-Guided Therapy.
Clin Infect Dis. 2023 Jun 16;76(12):2187-2195. doi: 10.1093/cid/ciad057.
3
and Activities of TP0480066, a Novel Topoisomerase Inhibitor, against Neisseria gonorrhoeae.
Antimicrob Agents Chemother. 2021 Mar 18;65(4). doi: 10.1128/AAC.02145-20.
4
PARMAP: A Pan-Genome-Based Computational Framework for Predicting Antimicrobial Resistance.
Front Microbiol. 2020 Oct 22;11:578795. doi: 10.3389/fmicb.2020.578795. eCollection 2020.
5
gyrA and parC mutations in fluoroquinolone-resistant Neisseria gonorrhoeae isolates from Kenya.
BMC Microbiol. 2019 Apr 8;19(1):76. doi: 10.1186/s12866-019-1439-1.
6
Alternations in DNA gyrase genes in low-level fluoroquinolone-resistant strains isolated in Poland.
Infect Drug Resist. 2018 Aug 6;11:1047-1053. doi: 10.2147/IDR.S162006. eCollection 2018.
7
Mutations in Neisseria gonorrhoeae grown in sub-lethal concentrations of monocaprin do not confer resistance.
PLoS One. 2018 Apr 5;13(4):e0195453. doi: 10.1371/journal.pone.0195453. eCollection 2018.
8
Draft Genome Sequence of Neisseria gonorrhoeae Strain NG_869 with Penicillin, Tetracycline and Ciprofloxacin Resistance Determinants Isolated from Malaysia.
Indian J Microbiol. 2016 Jun;56(2):225-7. doi: 10.1007/s12088-016-0568-6. Epub 2016 Feb 8.
9
Characterization of the novel DNA gyrase inhibitor AZD0914: low resistance potential and lack of cross-resistance in Neisseria gonorrhoeae.
Antimicrob Agents Chemother. 2015 Mar;59(3):1478-86. doi: 10.1128/AAC.04456-14. Epub 2014 Dec 22.
10
The use of platensimycin and platencin to fight antibiotic resistance.
Infect Drug Resist. 2013 Sep 18;6:99-114. doi: 10.2147/IDR.S25076.
本文引用的文献
1
Sentinel surveillance for antimicrobial resistance in Neisseria gonorrhoeae--United States, 1988-1991. The Gonococcal Isolate Surveillance Project Study Group.
MMWR CDC Surveill Summ. 1993 Aug 13;42(3):29-39.
2
High prevalence of Neisseria gonorrhoeae strains with reduced susceptibility to fluoroquinolones in Japan.
Genitourin Med. 1994 Apr;70(2):90-3. doi: 10.1136/sti.70.2.90.
3
Detection of the tetM determinant in Neisseria gonorrhoeae.
Sex Transm Dis. 1993 Nov-Dec;20(6):329-33.
4
Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones.
Mol Microbiol. 1994 Aug;13(4):641-53. doi: 10.1111/j.1365-2958.1994.tb00458.x.
5
Susceptibility of Neisseria gonorrhoeae associated with pelvic inflammatory disease to cefoxitin, ceftriaxone, clindamycin, gentamicin, doxycycline, azithromycin, and other antimicrobial agents.
Antimicrob Agents Chemother. 1994 Jul;38(7):1688-91. doi: 10.1128/AAC.38.7.1688.
6
Neisseria gonorrhoeae acquires mutations in analogous regions of gyrA and parC in fluoroquinolone-resistant isolates.
Mol Microbiol. 1994 Oct;14(2):371-80. doi: 10.1111/j.1365-2958.1994.tb01297.x.
7
DNA gyrase mutations in quinolone-resistant clinical isolates of Neisseria gonorrhoeae.
Antimicrob Agents Chemother. 1995 Feb;39(2):561-3. doi: 10.1128/AAC.39.2.561.
8
Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli.
Antimicrob Agents Chemother. 1990 Jun;34(6):1271-2. doi: 10.1128/AAC.34.6.1271.
9
Characterization of a gyrB mutation responsible for low-level nalidixic acid resistance in Neisseria gonorrhoeae.
Antimicrob Agents Chemother. 1991 Apr;35(4):622-6. doi: 10.1128/AAC.35.4.622.
Zotero 插件